How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Chemicals and Materials · Forecast 2027–2033
Isolongifolenone Market
- By Product Grade: Natural Isolongifolenone, Synthetic Isolongifolenone, Food Grade, Pharmaceutical Grade, Cosmetic Grade
- By Application: Fragrances and Perfumes, Flavoring Agents, Pharmaceuticals, Cosmetics and Personal Care, Food and Beverages
- By Form: Liquid, Powder, Crystalline
- By Purity Level: Standard Purity (90-95%), High Purity (95-99%), Ultra High Purity (99%+)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Natural Isolongifolenone leads By Product Grade at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 7 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 253 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 7 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Isolongifolenone Market report
A complete, evidence-based study - 11 chapters and 106 sections covering market size, segmentation across 4 axes, regional analysis and 7 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
7 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Wuhan Magic Biotechnology
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Minshan Chemical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Angene International Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Neostar United Industrial Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.173 →Suzhou Health Chemicals Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Hangzhou FandaChem Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Haihang Industry Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.191 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Natural Isolongifolenone38.8
- Synthetic Isolongifolenone15.1
- Food Grade23.5
- Pharmaceutical Grade11.6
- Cosmetic Grade11.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Wuhan Magic Biotechnology14.3
- Minshan Chemical23.4
- Angene International Limited4.7
- Neostar United Industrial Co. Ltd.11.4
- Suzhou Health Chemicals Co. Ltd.10.8
- Hangzhou FandaChem Co. Ltd.7.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe21.6
- Asia Pacific20.4
- Latin America14.4
- Middle East and Africa9.4
7 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Wuhan Magic Biotechnology | 97 | 81 | 84 | 94 | 79 | 94 | 88 |
| Minshan Chemical | 89 | 74 | 72 | 80 | 88 | 79 | 80 |
| Angene International Limited | 64 | 80 | 64 | 72 | 88 | 63 | 72 |
| Neostar United Industrial Co. Ltd. | 66 | 79 | 69 | 58 | 62 | 80 | 69 |
| Suzhou Health Chemicals Co. Ltd. | 63 | 65 | 74 | 73 | 57 | 61 | 66 |
| Hangzhou FandaChem Co. Ltd. | 46 | 50 | 52 | 61 | 51 | 62 | 54 |
| Haihang Industry Co. Ltd. | 64 | 48 | 40 | 63 | 43 | 59 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Wuhan Magic Biotechnology
- Minshan Chemical
- Angene International Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Wuhan Magic Biotechnology | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Minshan Chemical | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Angene International Limited | − | ◐ | ◐ | ◐ | ✓ | − |
| Neostar United Industrial Co. Ltd. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Suzhou Health Chemicals Co. Ltd. | − | ◐ | ◐ | ◐ | ◐ | − |
| Hangzhou FandaChem Co. Ltd. | − | − | ◐ | − | ◐ | ◐ |
| Haihang Industry Co. Ltd. | ✓ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Product Grade in North America, then scale across Isolongifolenone Market — a $269M beachhead inside a $4.40B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Natural Isolongifolenone
Best fit — highest urgency & budget in Product Grade.
Synthetic Isolongifolenone
Strong fit — clear ROI and a fast path to value.
Food Grade
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Grade in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Form
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Product Grade leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Isolongifolenone Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Isolongifolenone Market is a high-growth opportunity — $6.26B by 2033, compounding at 10.2%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Grade.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Grade moving from early to mainstream — durable secular demand.
Consolidation upside
7+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Isolongifolenone Market — a $1.03B market by 2033. Plan: grow share from 5.8% to 12.4%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 12.4% | Behind |
| Revenue | $60M | $128M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 30.7% | 39.6% | On track |
| Customer retention | 85.1% | 94.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Product Grade
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Grade share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $16M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Grade leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Sales deck · value proposition
Win the Isolongifolenone Market conversation — a $5.65B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Grade
Goal Grow share in Product Grade
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Isolongifolenone Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Isolongifolenone Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Chemicals and Materials · scroll →Isolongifolene Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportIsolongifolanone Market
Market size, share, segmentation and regional forecast.
$355M market · 2025 base year
View reportIsoleucine Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportIsolation Spray Market
Market size, share, segmentation and regional forecast.
$392M market · 2025 base year
View reportIsolation Joint Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportIsolation Gasket Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportIsolation and Dustproof System Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportIsolated High Elastic Antivibration Pad Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportIsolated Compressed Oxygen Self Rescuer Market
Market size, share, segmentation and regional forecast.
$457M market · 2025 base year
View reportIsohexanediol Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportIsohexadecane Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportIsoeugenol Methyl Ether Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy